MICA: RIVER - Recent HIV Infection Viral Eradication Research

Lead Research Organisation: Imperial College London
Department Name: Dept of Medicine

Abstract

Although treatment with antiretroviral therapy (ART) for HIV infection has markedly changed the life expectancy of people living with HIV, ART alone is unable to cure infection. This is because the virus is able to remain 'dormant' or latent for the life time of the infected person in certain cells of the body called the reservoir. It is for this reason that if ART is stopped the virus returns.

Researchers have recently identified certain very rare individual cases where it appears that HIV has in fact been to some extent "cured", through either very complicated treatment or very early ART at the time of birth.

In this study we will test whether starting ART as soon as an individual has become infected with HIV, followed by an HIV specific vaccination to strengthen the immune responses to HIV and another drug that forces virus out of the latently infected "reservoir" cells, may work in combination to reduce the number of latently infected cells. Research has shown that the fewer cells that contain 'latent viral infection' the better the chance the immune system has to control virus dividing without needing lifelong ART.

In the first place this study will test whether the combination of interventions in very recent HIV infection has the ability to make a significant reduction on the size of the viral reservoir; this is called a 'proof of concept' study and if effective may the lead onto further research.

Technical Summary

Antiretroviral therapy (ART) has revolutionised survival in HIV infection; however, alone, ART is unable to eradicate the virus because of an inaccessible pool of infected cells in which the virus is transcriptionally silent (the proviral reservoir).Eradication of HIV from reservoirs is likely to require at least two interventions: 1) Transcriptional activation of HIV from latently infected cells, 2) elimination of these re-activated cells.

We believe that Primary HIV Infection (PHI) represents the optimal timing for reservoir perturbation - the proviral reservoir is less established than in chronic disease, likely to be more susceptible to intervention and relatively homogeneous with limited time to incorporate viral escape mutations from the comparatively well preserved immune responses.

In vitro studies showed that Histone Deacetylase Inhibitor (HDACi) agents such as Vorinostat, Panobinostat and Romidepsin target specific histones associated with HIV repression leading to activation of viral transcription. Data from a single dose and 14-day dosing of vorinostat in HIV+ individuals with chronic infection on ART showed that HDACi led to a 5-fold and 2.5-fold increase in viral transcription, respectively. However, critically, neither study reported elimination of reactivated cells. Therefore, as an adjunct to HDACi administration, we propose an immunisation strategy to stimulate HIV-specific responses that will recognise and kill re-activated "reservoir cells". We will use a prime-boost immunisation with recombinant replication-defective chimpanzee adenovirus and modified vaccinia Ankara vaccines carrying conserved HIV sequences, previously demonstrated to induce high levels of HIV-specific, cytotoxic CD8+ T-cells.

This proof-of-concept study will test the hypothesis that a combination of HDACi-induced transcriptional activation, and potent HIV-specific T-cell immunisation at PHI, under ART suppression, will significantly reduce the proviral reservoir.

Planned Impact

Antiretroviral therapy (ART) has revolutionised survival in HIV infection. However, ART alone is unable to eradicate the virus because of an inaccessible pool of HIV infected cells in which the virus is transcriptionally silent (the proviral reservoir). In 2013, there will be >100,000 people living with HIV in the UK, costing >£1 billion annually. These costs are unsustainable. The most desirable goal both for individual patients and society is to understand how to eradicate HIV from the body.

Who will benefit from this research?
This research will benefit the academic community and people living with HIV (PLWH) for which a cure would represent an unprecedented step forward at times where treatment is a lifelong undertaking associated with toxicity and risk of resistance requiring treatment switch. In addition, in the absence of replicating virus the risk of onward viral transmission to sexual partners and infants would also be removed with a direct impact on the epidemic at population level. Hence, this research has the potential to benefit society at large by potentially impacting HIV incidence, as well as removing the burden of care provision for PLWH.

How will they benefit from this research?
Academic Community
Several approaches have been tested in a search for an HIV cure but none has yet been able to eradicate the reservoir of virus using scalable interventions. The study will be the first to investigate a combination approach and will provide critical information about the potential of HDACi accompanied by an immune stimulation. It is clear already that interruption of viral latency will require more than ART and HDACi and even a negative result from this proof of concept study will significantly move the field forwards.
Refinement of ultra low copy HIV viral load measurement and quantification of the HIV reservoirs using new technology represents an invaluable resource for the scientific community working on elucidating the mechanism by which a curecould be developed. These technologies can then be used in other intervention trials.
The collaborators have many years of successful internationally renowned experience in the field of HIV therapeutics, vaccine and prevention. This project will add to the continuation of their expertise as well as maintaining their training and development.

HIV infected community
The participants will have an opportunity to be involved in state-of-the-art study in an innovative area of research. Through community advisory board and interactions with patient groups, this will allow for public education and the research dissemination. Should the approach deliver a functional cure, the study participants would be the first beneficiaries of a long sought after therapy. Further, a cure would limit the known complications associated with continued HIV-mediated immune activation such as malignancy and cardiovascular disease. This would represent a significant alteration in quality of lifestyle, long-term clinical outcome and may confer a significant impact on HIV incidence at a population level.

National Health Services
A functional cure would have a direct impact on the cost associated with the management of PLWH and associated pathologies such as cardiac diseases, cancer and neurocognitive disorders.
The research will provide a basis for clinical decision making and policy-making for governments, policy-makers and advocates to develop evidence-based policies and advocacy aiming at prioritising investments in HIV research (clinical and basic science), allowing for an efficient use of limited funds, supporting research that has a greater potential to deliver results at population level.

Timescales for the benefits to be realised
The results could lead to a Phase 2 Trial within 2 years of completion.
Biological Samples collected during the study will contribute to a biobank that can be made available as soon as the study is completed for future investigation

Publications

10 25 50
publication icon
Abeler-Dörner L (2019) PANGEA-HIV 2: Phylogenetics And Networks for Generalised Epidemics in Africa. in Current opinion in HIV and AIDS

publication icon
Fatti G (2019) Better Virological Outcomes amongst People Living with HIV Initiating Early Antiretroviral Treatment (CD4 counts = 500 cells/µL) in the HPTN 071 (PopART) Trial in South Africa. in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

 
Title Animation for the RIVER trial 
Description We currently have in development with the UCL Health Creatives an animation to help explain how HIV is currently treated, why HIV cannot be cured, and the "Kick and Kill" theory that we are investigating in the RIVER trial. This short animation will consist of animated illustrations and a recorded voice-over. Our anticipated audience for this are potential RIVER study participants, and we aim to advertise this to recruiting sites and via the CHERUB Collaboration website as a useful tool to explain the concept of the study. 
Type Of Art Film/Video/Animation 
Year Produced 2016 
Impact No notable impact yet, as the animation is yet to be completed. 
 
Title CHERUB HIV Garden at the Royal Horticultural Society (RHS) Chelsea Flower Show, London, 22nd - 26th May, 2018 
Description Professor Fidler and the CHERUB (Collaborative HIV Eradication of viral Reservoirs) co-lead Professor Frater of Oxford University are leading on the organisation of the "CHERUB HIV Garden" which will be showcased at the RHS Chelsea Flower Show in London, on 22nd - 26th May 2018. "The CHERUB HIV Garden: A Life Without Walls" is focused on the journey a young person living with HIV takes and explores issues around stigma and openness. 
Type Of Art Artwork 
Year Produced 2018 
Impact Donations, publicity, PhD studentships, awareness of HIV and stigma surrounding HIV, awareness of HIV affecting people of all ages and backgrounds 
URL https://www.rhs.org.uk/shows-events/rhs-chelsea-flower-show/Gardens/2018/the-cherub-hiv-garden-a-lif...
 
Title CHIVA Film - Growing up with HIV 
Description This film is based on a workshop where people growing up with HIV discuss their experiences. Their narratives were made into a film script which was publicly shared on World Aids Day 2018. 
Type Of Art Film/Video/Animation 
Year Produced 2018 
Impact Widely shared through the internet and patient meetings. It was also shown at the BHIVA and CHIVA Conferences. 
URL https://www.chiva.org.uk/our-work/life-growing/
 
Description Fast Track Cities for HIV London
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Participation in a advisory committee
Impact The impact is improved access to HIV testing, treatment and prevention across London, towards zero new HIV infections.
 
Description HIV-1 Reservoir in Gut-Associated Lymphoid Tissue (GALT) in Primary HIV Infection
Amount £266,784 (GBP)
Funding ID MR/N001265/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 09/2015 
End 08/2018
 
Description HIV-1 Reservoir in Gut-Associated Lymphoid Tissue (GALT) in Primary HIV Infection
Amount £9,970 (GBP)
Organisation British HIV Association (BHIVA) 
Sector Charity/Non Profit
Country United Kingdom
Start 12/2015 
End 07/2017
 
Description Investigation of neuronal damage in HIV to Inform Future HIV-Cure Strategies
Amount £27,584 (GBP)
Organisation British HIV Association (BHIVA) 
Sector Charity/Non Profit
Country United Kingdom
Start 12/2016 
End 09/2019
 
Description Life growing up with HIV
Amount £2,200 (GBP)
Organisation Imperial College London 
Sector Academic/University
Country United Kingdom
Start 02/2018 
End 07/2018
 
Description The Indeterminate Retrovirus Infection Service (IDRIS); Novel testing, counselling and management of people with indeterminate HIV results
Amount £9,046 (GBP)
Funding ID BHIVA/1683/2018/Khan&MoraPeris 
Organisation British HIV Association (BHIVA) 
Sector Charity/Non Profit
Country United Kingdom
Start 12/2018 
End 07/2019
 
Description CHERUB: Collaboration on HIV eradication in the UK 
Organisation King's College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Through NIHR BRC funding we have developed a collaboration on HIV eradication research which includes patient recruitment, laboratory bio-banking, scientific assays development and clinical trials management on studies such as RIVER.
Collaborator Contribution Oxford University leads the laboratory assays, King's College London the biobank tissue repository, UCL the clinical trials management through MRC CTU at UCL, Cambridge runs some of the research assays and Imperial College London leads the overall collaboration administration and patient recruitment.
Impact Publications Additional funding from British HIV Association (BHIVA) MRC clinical fellowship PhD students Presentation at conferences Subsequent collaborations with international organisations Plenary presentations at international and national meetings
Start Year 2012
 
Description CHERUB: Collaboration on HIV eradication in the UK 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Through NIHR BRC funding we have developed a collaboration on HIV eradication research which includes patient recruitment, laboratory bio-banking, scientific assays development and clinical trials management on studies such as RIVER.
Collaborator Contribution Oxford University leads the laboratory assays, King's College London the biobank tissue repository, UCL the clinical trials management through MRC CTU at UCL, Cambridge runs some of the research assays and Imperial College London leads the overall collaboration administration and patient recruitment.
Impact Publications Additional funding from British HIV Association (BHIVA) MRC clinical fellowship PhD students Presentation at conferences Subsequent collaborations with international organisations Plenary presentations at international and national meetings
Start Year 2012
 
Description CHERUB: Collaboration on HIV eradication in the UK 
Organisation University of Cambridge
Country United Kingdom 
Sector Academic/University 
PI Contribution Through NIHR BRC funding we have developed a collaboration on HIV eradication research which includes patient recruitment, laboratory bio-banking, scientific assays development and clinical trials management on studies such as RIVER.
Collaborator Contribution Oxford University leads the laboratory assays, King's College London the biobank tissue repository, UCL the clinical trials management through MRC CTU at UCL, Cambridge runs some of the research assays and Imperial College London leads the overall collaboration administration and patient recruitment.
Impact Publications Additional funding from British HIV Association (BHIVA) MRC clinical fellowship PhD students Presentation at conferences Subsequent collaborations with international organisations Plenary presentations at international and national meetings
Start Year 2012
 
Description CHERUB: Collaboration on HIV eradication in the UK 
Organisation University of Oxford
Country United Kingdom 
Sector Academic/University 
PI Contribution Through NIHR BRC funding we have developed a collaboration on HIV eradication research which includes patient recruitment, laboratory bio-banking, scientific assays development and clinical trials management on studies such as RIVER.
Collaborator Contribution Oxford University leads the laboratory assays, King's College London the biobank tissue repository, UCL the clinical trials management through MRC CTU at UCL, Cambridge runs some of the research assays and Imperial College London leads the overall collaboration administration and patient recruitment.
Impact Publications Additional funding from British HIV Association (BHIVA) MRC clinical fellowship PhD students Presentation at conferences Subsequent collaborations with international organisations Plenary presentations at international and national meetings
Start Year 2012
 
Description RIVER study-clinical site management 
Organisation Medical Research Council (MRC)
Department MRC Clinical Trials Unit
Country United Kingdom 
Sector Public 
PI Contribution Imperial College is the trial sponsor and responsible for the overall project management of the award.
Collaborator Contribution The MRC-CTU is responsible for the management of the 6 clinical sites, and will also provide statistical analysis for the trial.
Impact no outcomes as trial has just started.
Start Year 2014
 
Description RIVER study-research partner 
Organisation University of Cambridge
Country United Kingdom 
Sector Academic/University 
PI Contribution Imperial College is the trial sponsor and provides overall management of the award.
Collaborator Contribution Cambridge University is a research partner and will perform immunological assays on trial patient samples
Impact No output/outcome as trial has recently started.
Start Year 2014
 
Description RIVER study-research partner 
Organisation University of Oxford
Country United Kingdom 
Sector Academic/University 
PI Contribution Imperial College, London is the trial sponsor and provides overall project management to the award.
Collaborator Contribution Oxford University is a research partner and will be performing assays on trial patient samples.
Impact The trial has just started so there are no outputs from this collaboration.
Start Year 2014
 
Title RIVER clinical trial 
Description The RIVER clinical trial will be testing the co-administration of ART (Raltegravir) and Vorinostat with a novel combination intervention strategy (Chimp adenovirus vaccine and MVA ) at Primary HIV infection (PHI) to provide a proof-of-concept that the ambitious challenge of HIV eradication is achievable. 
Type Therapeutic Intervention - Vaccines
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2015
Development Status Under active development/distribution
Impact No impacts yet as trial has just commenced. 
 
Description Academic Health Science Centre (AHSC) seminar series, Imperial College London 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Prof Fidler presented about HIV cure research public partnership at the third Academic Health Science Centre (AHSC) seminar held at Imperial College London.
Year(s) Of Engagement Activity 2016
URL http://www3.imperial.ac.uk/newsandeventspggrp/imperialcollege/newssummary/news_21-9-2016-12-46-20
 
Description 36 media articles and mentions about the RIVER trial and the 'Kick and Kill' strategy in the RIVER trial 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact The RIVER trial gained a lot of publicity at the AIDS 2018 Conference in Amsterdam, being the first randomised clinical trial to test the 'Kick and Kill' strategy. The trial and the results were also widely covered in media after the conference.
Year(s) Of Engagement Activity 2018
URL http://www.cherub.uk.net/wp-content/uploads/2019/03/RIVER-study-Kick-and-Kill-strategy-articles.pdf
 
Description 4th UK HIV and CNS Science Day 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Professor Fidler will present at the 4th annual UK HIV and CNS Science Day which is held at Chandos House, London, on 17th March 2017. Presentation title "HIV cure and the CNS".
Year(s) Of Engagement Activity 2017
URL https://www.eventbrite.co.uk/e/4th-uk-hiv-and-cns-day-2017-tickets-30923450874
 
Description AIDS 2018 Official Press Releases - The RIVER trial 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The RIVER study was included as part of the AIDS 2018 Official Press Releases, as one of the most notable studies to be reported at the conference.
Year(s) Of Engagement Activity 2018
URL http://www.aids2018.org/Media-Centre/The-latest/Press-releases/ArticleID/185/HIV-studies-provide-cri...
 
Description AIDS and Antiviral Research Conference, Milan, Italy 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Professor Fidler presented an update on HIV cure and the management of acute infection at the Italian Conference on AIDS and Antiviral Research in Milan, June 2016.
Year(s) Of Engagement Activity 2016
URL http://www.icar2016.it/
 
Description Ageing with HIV Conference, European AIDS Treatment Group, Bucharest, Romania 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Professor Fidler was invited to present on treatment and cure for HIV, at the Ageing with HIV Conference, for the European AIDS Treatment Group, in Bucharest, Romania.
Year(s) Of Engagement Activity 2017
URL https://www.ageingwithhiv.com/presentations
 
Description Animation about the RIVER trial 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact A short animation was created to assist with the recruitment into the RIVER study. It has proven to be a valuable resource.
Year(s) Of Engagement Activity 2016
URL http://www.cherub.uk.net/new-animation-explaining-the-river-study-design/
 
Description BHIVA Autumn Conference, London 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Professor Fidler was invited to delivery a plenary talk on Post-treatment control at the British HIV Association (BHIVA) Annual autumn conference.
Year(s) Of Engagement Activity 2016
URL http://www.bhiva.org/Presentations161014.aspx
 
Description British Association for Sexual Health and HIV (BASHH) Annual Conference, Belfast 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Professor Fidler has been invited to give a plenary talk at the annual BASHH conference in Belfast: "An update on HIV cure".
Year(s) Of Engagement Activity 2017
 
Description British HIV and Sexual Health and HIV (BASHH) - HIV Masterclass, Manchester 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Prof Fidler will present at the BASHH HIV Masterclass on HIV Cure Strategies.
Year(s) Of Engagement Activity 2017
 
Description CHERUB HIV Garden at the Royal Horticultural Society (RHS) Chelsea Flower Show, 22nd - 26th May, 2018 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Supporters
Results and Impact Professor Fidler and CHERUB (Collaborative HIV Eradication of viral Reservoirs) co-lead Professor Frater of Oxford University are leading on the organisation of the HIV Garden which will be showcased at the RHS Chelsea Flower Show on 22nd - 26th May 2018. "The CHERUB HIV Garden: A Life Without Walls" is focused on the journey a young person living with HIV takes and explores issues around stigma and openness.
Year(s) Of Engagement Activity 2018
URL https://www.rhs.org.uk/shows-events/rhs-chelsea-flower-show/Gardens/2018/the-cherub-hiv-garden-a-lif...
 
Description Chairing and presenting the patient results meeting for the RIVER trial, 18th July 2018 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Study participants or study members
Results and Impact Professor Fidler presented the results of the RIVER clinical trial ("Research In Viral Eradication of HIV Reservoirs") to the study participants and their families at the RIVER patient results meeting held at Imperial College London on the 18th of July 2018. Further feedback from the study participants about being part of the RIVER trial has been very positive, even though the study result was in itself not what they had hoped for. The meeting also enabled networking amongst the participants and the study team.
Year(s) Of Engagement Activity 2018
 
Description Dr Sarah Fidler interviewed on Radio 4's The World Tonight programme 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Dr Sarah Fidler was interviewed on Radio 4's The World Tonight programme to discuss the UNAIDS report and HIV cure on Wednesday, 16th July 2014.
Year(s) Of Engagement Activity 2014
 
Description Dr Sarah Fidler interviewed on the Newsnight programme on BBC2 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Dr Sarah Fidler contributed to a discussion on the BBC's Newsnight programme about HIV cure.
Year(s) Of Engagement Activity 2013
 
Description Flyers for the RIVER trial 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Study participants or study members
Results and Impact The RIVER study flyers have been circulated to the national HIV organisations; Terrence Higgins Trust, Positively UK and through the UKCAB mailing lists - the mailing list reaches 106 HIV related organisations and about 800 members.
Year(s) Of Engagement Activity 2016
 
Description Interview with The Guardian Upside Science, Nov 2018 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact Professor Fidler was interviewed by The Guardian Upside Science for their feature on HIV cure "Is a cure for Aids within reach?" to coincide with the World AIDS Day in 2018.
Year(s) Of Engagement Activity 2018
URL https://www.theguardian.com/world/2018/nov/30/cure-for-hiv-world-aids-day
 
Description Interview with the Sunday Times 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Professor Fidler was interviewed by the Sunday Times on HIV cure and the RIVER trial where first participant had finished the intervention. The article sparked world-wide interest in the trial.
Year(s) Of Engagement Activity 2016
 
Description Invited plenary lecture on HIV cure at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Madrid 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Professor Fidler has been invited to give a plenary lecture titled "Treatment of HIV during acute and early phase of infection" at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) which is held at the 21-14 April, 20018 in Madrid, Spain.
Year(s) Of Engagement Activity 2018
URL http://www.eccmid.org/
 
Description Invited speaker at the HIV Cure Minisymposium, Frontiers in Retrovirology Conference 2018, Leuven, Belgium 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Professor Fidler had been invited to present at the Frontiers in Retrovirology Conference in Leuven, Belgium, in September 2018, at the HIV Cure Minisymposium. The title of her presentation is "Strategies towards a cure for HIV".
Year(s) Of Engagement Activity 2018
URL https://kuleuvencongres.be/frontiers-in-retrovirology2018/pages/program
 
Description Invited speaker at the The International Congress on Drug Therapy in HIV infection, Glasgow, October 2018 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Professor Fidler was invited to give a talk at The International Congress on Drug Therapy in HIV infection, held in Glasgow in October 2018. Her presentation title was: "Approaches towards a cure for HIV".
Year(s) Of Engagement Activity 2018
URL http://www.hivglasgow.org/scientific-programme-2018
 
Description Invited talk on HIV cure research at the Rockefeller University, New York 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Postgraduate students
Results and Impact Professor Fidler has been invited to give a talk on HIV cure research at the Rockefeller University in New York in May 2018.
Year(s) Of Engagement Activity 2018
 
Description Media interviews and statements by Prof Sarah Fidler, in relation to the cured London patient and the results of the HPTN 071 PopART clinical trial 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact 1) Prof Fidler was interviewed by UK media in relation to the cured patient in London called 'The London Patient'. The patient became the second person in the world to be cleared of the HIV virus after stem cell donation. Prof Ravindra Gupta of UCL, who treated the patient, is part of the CHERUB Collaboration; one of the first cooperatives of UK Biomedical Research Centres to explore one of the most exciting new fields of biomedical research - HIV Cure. Prof Fidler is the co-Chair of the CHERUB Collaboration.

2) Prof Fidler was interviewed by UK media in relation to the findings of the HPTN 071 PopART trial where she was the co-Chair of the trial protocol. The HPTN 071 PopART trial is the largest community-randomised trial of the universal HIV 'test and treat' strategy to date. The study was carried out in 21 communities (12 communities in Zambia and 9 in the Western Cape province of South Africa) from 2013 to 2018, and the study reported its findings at the CROI Conference in Seattle on 4th March 2019. The randomised study involving around one million people in Zambia and South Africa, found that new HIV infections were 30% lower in communities where this intervention was introduced alongside offering other proven HIV prevention measures to those who tested negative, compared to communities that received standard care.
Year(s) Of Engagement Activity 2019
URL http://www.cherub.uk.net/wp-content/uploads/2019/03/Imperial-College-London-Media-Coverage-Report-Ma...
 
Description Panel discussion on HIV cure research at the at the fifth annual WIRED Health conference held at the Francis Crick Institute in London 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Professor Fidler has been invited to take part in a panel discussion on HIV cure research at the fifth annual WIRED Health conference held at the Francis Crick Institute in London, on the 13th March 2018.
Year(s) Of Engagement Activity 2018
URL http://www.wired.co.uk/article/wired-health-2018-about
 
Description Patient feedback meeting for the HEATHER clinical trial, London 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Study participants or study members
Results and Impact Professor Fidler presented the latest work of the HEATHER clinical trial ("HIV Reservoir Targeting with Early Antiretroviral Therapy") to the study participants and their families at the annual HEATHER patient feedback meeting held at Imperial College, London on the 25th September 2017.
Year(s) Of Engagement Activity 2017
 
Description Patient feedback meeting for the RIVER clinical trial, London 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Study participants or study members
Results and Impact Professor Fidler presented the latest work of the RIVER clinical trial ("Research In Viral Eradication of HIV Reservoirs") to the study participants and their families at the first RIVER patient feedback meeting held at Imperial College, London on the 18th January 2018.
Year(s) Of Engagement Activity 2018
 
Description Plenary lecture on HIV research into cure at the International Congress of Drug Therapy in HIV infection in Glasgow 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Professor Fidler has been invited to give a plenary lecture on HIV research into cure, at the International Congress of Drug Therapy in HIV infection, held in Glasgow, on the 28-31 October, 2018.
Year(s) Of Engagement Activity 2018
URL http://www.hivglasgow.org/
 
Description Presentation about HIV cure at the HIV Cure Minisymposium 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Professor Fidler will give a talk about HIV cure, at the 3rd HIV Cure Minisymposium on 13th September 2018 in Leuven, Belgium.
Year(s) Of Engagement Activity 2018
 
Description Presentation at the 28th European Congress of Clinical Microbiology and Infectious Diseases - ECCMID, Madrid, Spain, 21-24 April, 2018 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Professor Fidler presented "Treatment of HIV during acute and early phase of infection" as part of the session "Novel approaches in functional cure and prevention of HIV/AIDS".
Year(s) Of Engagement Activity 2018
URL https://www.escmid.org/fileadmin/eccmid/2018/media/documents/escmid-final-programme-madrid-web.pdf
 
Description Presentation for UK CAB on the RIVER trial 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Patients, carers and/or patient groups
Results and Impact Dr Fidler gave a talk on HIV cure and the RIVER study to 32 UK CAB members. UK CAB is a network for community HIV treatment advocates across the UK. They provide feedback to doctors and scientists from the point of view of the patients and thus are an invaluable resource. This talk also enabled direct links be made regarding enrollment on the RIVER trial and the participating clinics.
Year(s) Of Engagement Activity 2015
 
Description Presentation to the Department of Medicine, Imperial College London, August 2018 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Other audiences
Results and Impact Professor Fidler presented the RIVER trial and the trial results, to the Department of Medicine, Imperial College London, on the 29th August 2018.
Year(s) Of Engagement Activity 2018
 
Description RIVER trial notification on Imperial College London website 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Postgraduate students
Results and Impact The RIVER trial was first advertised on the Imperial College London website in 2013, as Dr Fidler, Principal Investigator for RIVER, is affiliated with Imperial College London.
Year(s) Of Engagement Activity 2013
URL http://www3.imperial.ac.uk/newsandeventspggrp/imperialcollege/newssummary/news_26-11-2013-10-28-14
 
Description RIVER trial press release 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Patients, carers and/or patient groups
Results and Impact The RIVER trial officially opened for enrolment in December 2015 and this is when the press release was also published.
Year(s) Of Engagement Activity 2015
 
Description RIVER trial results presentation at the AIDS2018 Official Press Conference titled "HIV Treatment and Cure Research Highlights" - July 24th 2018, 22nd International AIDS Conference (AIDS2018) 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact As the Chief Investigator of the RIVER trial; the first randomised controlled trial of a "kick and kill" approach to attacking HIV reservoirs, Professor Fidler was invited to present the trial results at the AIDS2018 Official Press Conference on Tuesday, 24th July 2018. The session was called "HIV Treatment and Cure Research Highlights". The RIVER study was selected as one of the important key trial results for the main conference, and was the focus of a press release from the conference organisers, as well as the subject of a key media debate in the HIV cure field.
Year(s) Of Engagement Activity 2018
URL https://www.aids2018.org/Media-Centre/Resources/Press-programme
 
Description Roundtable discussion at The 10th International Workshop on HIV Pediatrics, Amsterdam, 20th July 2018 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Professor Fidler was invited to join the roundtable discussion for the session "Pediatric Care and Treatment" with the proposed presentation title "Talking with parents and children/youth about cure research", at The 10th International Workshop on HIV Pediatrics, that took place on 20-21 July 2018 in Amsterdam.
Year(s) Of Engagement Activity 2018
URL https://www.virology-education.com/event/previous/10th-workshop-hiv-pediatrics/
 
Description Roundtable discussion on HIV cure, AIDS 2018 Conference, Amsterdam, July 25th 2018 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Professor Fidler was invited to a roundtable discussion on HIV cure with Prof Anthony Fauci and Prof Sharon Lewin, on Thursday, 26th July 2018 at the AIDS2018 Conference. The RIVER study was selected as one of the important key trial results for the AIDS2018 Conference, and was the focus of a press release from the conference organisers, as well as the subject of a key media debate in the HIV cure field.
Year(s) Of Engagement Activity 2018
 
Description Royal Pharmaceutical Society, London 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Prof Fidler presented about HIV vaccines and cure at the Royal Society of Pharmacists.
Year(s) Of Engagement Activity 2016
 
Description Talk at HIV Scotland on the RIVER trial 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact Mr Damian Kelly, the Patient Advocate for the RIVER trial, gave a talk at HIV Scotland in February 2016 about the RIVER trial and CURE research. HIV Scotland is the national HIV policy organisation for Scotland. Around 100 people attended this conference and the attendees included government representatives, patients, doctors and other care providers as well as policy makers. It was an important event for all concerned and an important opportunity to advertise the RIVER trial.
Year(s) Of Engagement Activity 2016
 
Description Talk at the Final Honour School (FHS) students, Oxford University, 12 Mar 2018 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Undergraduate students
Results and Impact Professor Fidler gave a talk at the Final Honour School (FHS) in Oxford University on HIV medicine.
Year(s) Of Engagement Activity 2018
 
Description The CHERUB Collaboration Annual Scientific Workshop 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact The 6th Annual CHERUB Scientific Workshop took place on 24th November 2018, at Imperial College London. As the co-lead of the CHERUB Collaboration with Prof John Frater, Oxford, Professor Fidler co-chaired the meeting, and presented the RIVER trial results.
Year(s) Of Engagement Activity 2018
 
Description The official RIVER trial results presentation, July 24th 2018, at The 22nd International AIDS Conference, Amsterdam 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Professor Fidler presented the RIVER trial results as an oral presentation at the AIDS 2018 Conference on Tuesday, 24th July 2018. The session was called "Strategies for cure: Pitfalls, possibilities and promise". The RIVER study was selected as one of the important key trial results for the AIDS2018 Conference, and was the focus of a press release from the conference organisers, as well as the subject of a key media debate in the HIV cure field.
Year(s) Of Engagement Activity 2018
URL http://programme.aids2018.org/Programme/Session/140
 
Description The official press release for the RIVER trial - Imperial College London 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact The officlal press release for the RIVER trial, from Imperial College London, Tuesday, 24th July 2018, to co-incide with the press conference at the AIDS 2018 Conference.
Year(s) Of Engagement Activity 2018
URL https://www.imperial.ac.uk/news/187372/trial-kick-kill-approach-hiv-cure/
 
Description Twitter account for the CHERUB Collaboration, including RIVER 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact Twitter account for the CHERUB Collaboration of which the RIVER trial is part of. The Twitter account reaches thousands of people across the world and it is one of the best ways to communicate real time news and updates regarding the associated studies.
Year(s) Of Engagement Activity 2015,2016
 
Description Website for CHERUB Collaboration, including RIVER 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact The website for the CHERUB Collaboration was established in 2012. The RIVER trial is an associated trial and it is well advertised on the CHERUB website. Queries regarding enrolment on RIVER and other trials available via CHERUB, are received through the CHERUB mailing list on a weekly basis.
Year(s) Of Engagement Activity 2012,2013,2014,2015,2016